The Board of Directors of Blue Cross Blue Shield of Massachusetts (BCBSMA) has chosen Executive Vice President Andrew Dreyfus as the company's new president and chief executive officer. Dreyfus succeeds Bill Van Faasen who has served in an unpaid interim role of president and CEO since March 16, 2010.
The Board of Directors of Blue Cross Blue Shield of Massachusetts (BCBSMA) has chosen Executive Vice President Andrew Dreyfus as the company's new president and chief executive officer. Dreyfus succeeds Bill Van Faasen who has served in an unpaid interim role of president and CEO since March 16, 2010. Van Faasen will remain involved with the company in a role still to be determined.
"Andrew is not only an experienced leader in the industry and a nationally known expert on critical issues such as health reform and changing the way we pay for care, but as importantly, he has a broad understanding and passionate commitment to continuing and strengthening the important leadership role BCBSMA has played in our community since the company's founding 73 years ago," said BCBSMA Board Chairman Paul Guzzi in a statement announcing the decision.
Over the past five years, Dreyfus has served as BCBSMA's executive vice president for Health Care Services. He also led the development and execution of the company's Alternative Quality Contract (AQC), a new payment model that aligns physician and hospital payments with the quality of care patients receive.
Dreyfus has been a part of BCBSMA's executive leadership team since 2001, when he was selected as the first president of the Blue Cross Blue Shield of Massachusetts Foundation. Prior to joining BCBSMA in 2001, Dreyfus was an executive vice president at the Massachusetts Hospital Association and held senior positions in the Massachusetts Executive Office of Human Services and the Executive Office of Consumer Affairs and Business Regulation.
FDA Site Inspections Decreased During Pandemic. Questions Continue about Drug Quality.
December 4th 2023A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
RSV Vaccines for Adults: Gaps in Understanding
December 4th 2023Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen